Status:
RECRUITING
Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome
Lead Sponsor:
McGill University
Conditions:
PCOS
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) ris...
Eligibility Criteria
Inclusion
- All female participants will report female sex assigned at birth
- All participants will be aged 18 to 40
- PCOS diagnosis
Exclusion
- Current smokers or a prolonged history of smoking
- Presence or history of overt cardiometabolic disease (e.g., stage 2 hypertension, diabetes, heart disease), neurologic disease, or endocrinopathy (with the exception of PCOS)
- Current pregnancy or currently breastfeeding
- Current use of medications which may affect our outcomes of interest (e.g., anti-hypertensives, anti-androgens, metformin)
Key Trial Info
Start Date :
January 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06155708
Start Date
January 20 2025
End Date
December 1 2027
Last Update
January 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiovascular Health and Autonomic Research Laboratory
Montreal, Quebec, Canada, H2W 1S4